Progressive Fibrosis

Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.

Progressive fibrosing interstitial lung disease was associated with poorer survival in patients with connective tissue disease-associated ILDs, according to new results published in Respiratory Medicine.